Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.

80 mg/m2, IV (in the vein) weekly for 12 weeks.

60 mg/m2, IV (in the vein) every 14 days for 4 doses.

600 mg/m2, IV (in the vein) every 14 days for 4 doses.